ETA receptor‐mediated responses to endothelin‐1 and big endothelin‐1 in the rat kidney
- 1 March 1994
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 111 (3) , 729-732
- https://doi.org/10.1111/j.1476-5381.1994.tb14798.x
Abstract
1. Renal clearance experiments were conducted in anaesthetized Sprague-Dawley rats to determine the effect of the ETA receptor antagonist, BQ-123, on the renal haemodynamic response to endothelin-1 (ET-1) and its precursor, big endothelin-1 (big ET-1) at doses that produce an equivalent degree of renal vasoconstriction. 2. Infusion of either big ET-1 at 100 pmol kg-1 min-1 or ET-1 at 12 pmol kg-1 min-1 for 60 min produced almost identical decreases in renal blood flow (RBF) and glomerular filtration rate (GFR). Big ET-1 produced an increase in mean arterial pressure (MAP) that was significantly larger than the increase produced by ET-1. 3. Co-infusion with BQ-123 (0.1 mg kg-1 min-1) prevented the rise in MAP produced by big ET-1 and completely blocked the renal response. Similarly, BQ-123 inhibited both the increase in MAP and the decrease in RPF and GFR produced by ET-1. 4. Big ET-1 but not ET-1, produced a significant increase in water and sodium excretion. BQ-123 had no effect on the diuretic and natriuretic response to big ET-1 consistent with possible ETB-mediated inhibition of tubular reabsorption. 5. We have previously shown that at higher doses of ET-1, BQ-123 was unable to inhibit the renal vasoconstrictor response despite blockade of the pressor response. Taken together, these results indicate that ET-1 activates primarily ETA receptors at moderately low doses to produce renal vasoconstriction while higher doses also involve non-ETA receptors. 6. Since ET-l has a similar binding affinity for both ETA and ETB receptors, we suggest that there maybe a third type of ET-1 receptor in the rat kidney with lower affinity for ET-1 that is coupled to a vasoconstrictor mechanism.Keywords
This publication has 22 references indexed in Scilit:
- A specific endothelin subtype A receptor antagonist protects against injury in renal disease progressionKidney International, 1993
- Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidneyKidney International, 1993
- Effects of Neutral Endopeptidase Inhibition on the Clearance of Exogenously Administered Endothelin in Sprague-Dawley RatsJournal of Cardiovascular Pharmacology, 1993
- The vasoconstrictor action of big endothelin-1 is phosphoramidon-sensitive in rabbit saphenous artery, but not in saphenous veinEuropean Journal of Pharmacology, 1992
- Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in ratsEuropean Journal of Pharmacology, 1992
- BQ-153, a novel endothelin (ET)A antagonist, attenuates the renal vascular effects of endothelin-1Journal of Pharmacy and Pharmacology, 1992
- The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivoBiochemical and Biophysical Research Communications, 1992
- Role of neutral endopeptidase in the metabolism of endothelin.Hypertension, 1992
- Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay.Journal of Clinical Investigation, 1992
- Endothelin-1 and Endothelin-3 Release EDRF from Isolated Perfused Arterial Vessels of the Rat and RabbitJournal of Cardiovascular Pharmacology, 1989